

## Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB

**Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB.**

The Company has entered into an agreement with Carnegie Investment Bank AB regarding the position as Certified Adviser. Carnegie Investment Bank AB will take over as Certified Adviser on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser to the company.

**For further information, please contact:**

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: [peter.nordkild@asarinapharma.com](mailto:peter.nordkild@asarinapharma.com)

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Tel: +45 5132 3698

E-mail: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

The Company's Certified Adviser is Carnegie Investment Bank AB (publ)

**About Asarina Pharma**

Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSAs compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

**Attachments**

[Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB](#)